Read our latest: CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via HR. The findings of this study may open additional clinical avenues to improve outcomes. From Blueprint Medicines academic.oup.com/narcancer/arti…

Read our latest: Proteasome dysfunction increases APOBEC3A abundance, potentially increasing genetic heterogeneity and thereby influencing therapeutic responses. From Margo Coxon, Steven A Roberts and coworkers UVM Cancer Center academic.oup.com/narcancer/arti…

New in NAR Cancer. A resource to guide functional studies: a compendium of long noncoding RNAs associated with tumor, immune, or stromal cells in pancreatic cancer. From @ChrisMaher and coworkers. WashU Siteman Cancer Center #lncrnas #bioinformatics. academic.oup.com/narcancer/arti…

Sad to hear of this loss to the community.

Read our latest: linking metabolic reprogramming to rewiring of RNA methylation in renal cell carcinoma. From Pedro Batista lab Pedro Batista National Cancer Institute . academic.oup.com/narcancer/arti…

Read our latest: Dysregulation of the ORigin FIring Under Stress (ORFIUS) complex may promote high grade serous ovarian cancer survival after DNA damage. From the Sarah J. Hill lab Dana-Farber academic.oup.com/narcancer/arti…

Read our latest: expression level of bifunctional glycosylase/AP lyase NTHL1 controls cisplatin sensitivity in lung epithelial and NSCLC cells. From Anirban Kar, Natalya Degtyareva, Paul Doetsch @niehs academic.oup.com/narcancer/arti…

Read our latest" SAMHD! expression contributes to doxorubicin resistance and predicts survival outcomes in diffuse large B-cell lymphoma. From Waaqo Daddacha, David S. Yu and coworkers Winship Cancer Institute of Emory University Augusta University academic.oup.com/narcancer/arti…

Read our latest Editor's Choice article: HDAC10 inhibition represses melanoma cell growth and BRAF inhibitor resistance via upregulating SPARC expression. From Ed Seto and coworkers at GWU Cancer Center. academic.oup.com/narcancer/arti…

Read our latest: "Metabolism-dependent secondary effect of anti-MAPK cancer therapy on DNA repair." Decreases in aspartate and glutamate bioavailability have widespread effects. From Fabien Aubé, Nicolas Fontrodona, Didier Auboeuf, and coworkers. academic.oup.com/narcancer/arti…

New in NAR Cancer: Next generation technologies to address aberrant translation in cancer, explained and critically reviewed. From Angél Román and colleagues, Universidad de Extremadura, Spain. From our new Translation and Cancer collection. academic.oup.com/narcancer/arti…

New in NAR Cancer: Introducing the MEnet tool for neural net based cell deconvolution from DNA methylation - reveals tumor microenvironment associated with prognosis. From Naganari Ohkura and colleagues, Kyoto University. academic.oup.com/narcancer/arti…

Congratulations to Nucleic Acids Res on their 50th!

Mechanistic insights into generation of highly mutagenized extrachromosomal DNAs in cancer. Implications for neoantigens and therapy resistance. Read the latest from Rujuta Gadgil, Michael Leffak, and coworkers Wright State University (Dayton, OH) academic.oup.com/narcancer/arti…

Read our latest: Nucleoside supplementation rescues all phenotypes associated with PARG inhibitor sensitivity. From @Prof_S_Taylorl lab, Manchester Cancer Research Centre Manchester Cancer Research Centre. academic.oup.com/narcancer/arti…

Xisca and me have curated a collection on translational regulation and #cancer, out now in NAR Cancer Editor-in-Chief 🔗academic.oup.com/narcancer/page… Contributions from Lorenzo Montanaro Millevoi Stefania Gebauer Lab John Prensner Catherine Denicourt Sandra Blanco Lab William Faller and others #RNA #RBP

Exciting special collection for 2024. Read the editorial from editors Erik Dassi and Xisca: "Translational control in cancer" introducing 11 new review articles and 14 related articles from our archive. academic.oup.com/narcancer/arti…

Read the most recent contribution to our 2024 special collection on Translational Control in Cancer.

Read our latest: Abasic sites as therapeutic targets to synergize temozolomide response. From Sanjay Dutta and coworkers. academic.oup.com/narcancer/arti…

Read our latest: BRCA1 and RAD51C methylation surveyed across 23 solid cancers - required for HR deficiency and possible therapeutic biomarker. From Olga Kondrashova and coworkers, QIMR Berghofer Medical Research Institute. academic.oup.com/narcancer/arti…